Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04070326 · ClinicalTrials.gov registry record · Phase 3
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
NCT04070326 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 21 participants.
The verdict
NCT04070326, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
Study Summary
The main aims of this study are to learn how lanadelumab moves through a child's body and if the children have any medical problems from lanadelumab. Other aims are to learn if prophylactic treatment with lanadelumab reduces the number and severity of HAE attacks in children, how lanadelumab affects the child's body, and if the children develop antibodies to lanadelumab. The study doctors will treat acute HAE attacks according to their standard practice. Participants will receive lanadelumab for up to 52 weeks. When they start treatment, participants will visit their clinic every week for the first 4 weeks. Then, they will visit their clinic every 4 weeks during treatment.
Interventions
- DRUG Lanadelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2021-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04070326
The ClinicalTrials.gov registry entry for NCT04070326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanadelumab is the first listed.
NCT04070326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04070326 about?
NCT04070326 is a clinical study titled "A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children". The main aims of this study are to learn how lanadelumab moves through a child's body and if the children have any medical problems from lanadelumab. Other aims are to learn if prophylactic treatment with lanadelumab reduces the number and severity of HAE attacks in children, how lanadelumab affects...
What is the current status of trial NCT04070326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2019-08-19. Estimated completion is 2021-10-30.
What interventions are being tested in trial NCT04070326?
The interventions under investigation include: Lanadelumab (DRUG).
Who is sponsoring clinical trial NCT04070326?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.